Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 1
2004 7
2005 3
2006 5
2007 2
2008 7
2009 6
2010 11
2011 17
2012 13
2013 18
2014 25
2015 21
2016 12
2017 12
2018 12
2019 14
2020 20
2021 22
2022 17
2023 13
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Results by year

Filters applied: . Clear all
Page 1
Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Ii.
Gaudreault M, Hardcastle N, Jackson P, McIntosh L, Higgs B, Pryor D, Sidhom M, Dykyj R, Moore A, Kron T, Siva S. Gaudreault M, et al. Among authors: kron t. Int J Radiat Oncol Biol Phys. 2024 Apr 26:S0360-3016(24)00564-9. doi: 10.1016/j.ijrobp.2024.04.066. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38679212
Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas.
Yu KK, Yeo A, Ngan S, Chu J, Chang D, Siva S, Wong A, Kron T, Hardcastle N, Gaudreault M, Chesson T, Williams S, Burns M, Chander S. Yu KK, et al. Among authors: kron t. Radiother Oncol. 2024 Apr 21:110275. doi: 10.1016/j.radonc.2024.110275. Online ahead of print. Radiother Oncol. 2024. PMID: 38653378 No abstract available.
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Siva S, et al. Among authors: kron t. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. Lancet Oncol. 2024. PMID: 38423047 Clinical Trial.
Dose-Response Relationship Between Radiation Therapy and Loss of Lung Perfusion Comparing Positron Emission Tomography and Dual-Energy Computed Tomography in Non-Small Cell Lung Cancer.
Gaudreault M, Bucknell N, Woon B, Kron T, Hofman MS, Siva S, Hardcastle N. Gaudreault M, et al. Among authors: kron t. Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):1135-1143. doi: 10.1016/j.ijrobp.2023.10.038. Epub 2023 Oct 31. Int J Radiat Oncol Biol Phys. 2024. PMID: 37914141
Impact on Pulmonary Function in a Randomized Trial of Single-Fraction and Multifraction Stereotactic Body Radiation Therapy for Pulmonary Oligometastatic Disease: An Analysis of TROG 13.01 (SAFRON II).
Bucknell NW, Hardcastle N, Bressel M, Moore A, Montgomery R, Murnane A, Mai GT, Ball D, Kron T, Siva S. Bucknell NW, et al. Among authors: kron t. Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):944-951. doi: 10.1016/j.ijrobp.2023.09.052. Epub 2023 Oct 21. Int J Radiat Oncol Biol Phys. 2024. PMID: 37871885 Clinical Trial.
242 results